eFFECTOR Therapeutics (EFTR): שווי מצרפי של הפעילות העסקית

Despite the absolute independence of biotech demand from macroeconomic cycles, eFFECTOR Therapeutics (EFTR) ceased operations and liquidated its assets following failed drug trials in mid-2024. This chart on the GURU.Markets platform shows the enterprise value at . Currently, business development is being hindered by geopolitical risks, which are blocking international logistics and the conduct of global clinical trials.

For a conservative investor, the aggregate valuation of eFFECTOR Therapeutics (EFTR) assets, calculated as the sum of market capitalization and net debt, serves as an objective measure of the cost of a full business acquisition. In the case of eFFECTOR Therapeutics (EFTR), this indicator reflects the real cost of ownership for a unique scientific protein translation platform, which retains leading biochemists through intellectual capital and stock option programs, thereby determining the issuer's long-term investment attractiveness.